BOSTON BIOMEDICAL INC
AI strategy consulting and implementation services for midsized companies
- Sector
- UNCERTAIN
- Headquarters
- Norwood, MA
- Founded
- 2006
- Latest Form D
- $2M, Jun 2010
- Total capital
- $3.5M
- Federal grants
- $1.5M
- 4 awards · 2008–2011
- 4.0× sector median 1 award
- Private capital raised
- $2M
- 1 Form D · last Jun 2010
- 197 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 12
- 28 pending · first 2015
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Development of Specific Gene Silencing Methods and Reagents$312K
- Private capital raisedForm D · SEC · 1st filing$2M
- Federal grantHealth and Human S · Phase I · Development of aiRNA technology$486K
- Federal grantHealth and Human S · N43 · Biomedical (basic)$222K
- Federal grantHealth and Human S · Phase I · Cancer targeted therapy through bacterial RNAi$437K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
23months
from BOSTON BIOMEDICAL INC’s first federal award to its first private round.
- First federal award · Jul 2008
- Health and Human S · $437K
- First Form D · Jun 2010
- $2M · 1st Form D
- Awards before first raise
- 3 awards
An association in public records, not a cause or a prediction.
Founders and team
From SEC Form D filings- Chiang J. LiExecutive Officer, DirectorNamed in SEC Form D filings
- Joel S. MarcusDirectorNamed in SEC Form D filings
- Taro J. InabaDirectorNamed in SEC Form D filings
- William J. RutterDirectorNamed in SEC Form D filings
What it has protected
USPTO · 12 granted of 40- GrantedNew Tricyclic Quinone DerivativeUSPTOUS 10,934,309
- Granted3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE Derivative Or Pharmaceutically Acceptable Salt ThereofUSPTOUS 10,683,274
- GrantedMethods For Treating CancerUSPTOUS 10,646,464
Show all 40 patent records
- New Tricyclic Quinone DerivativeMar 2, 2021 · US 10,934,309Granted
- 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE Derivative Or Pharmaceutically Acceptable Salt ThereofJun 16, 2020 · US 10,683,274Granted
- Methods For Treating CancerMay 12, 2020 · US 10,646,464Granted
- Novel Group Of STAT3 Pathway Inhibitors And Cancer Stem Cell Pathway InhibitorsFeb 6, 2020 · Application 16236948Pending
- 2-ACETYLNAPHTHO[2,3-B]FURAN -4,9-DIONE For Use On Treating CancerJan 28, 2020 · US 10,543,189Granted
- Novel Methods For Treating CancerAug 29, 2019 · Application 16170634Pending
- Compositions Of Kinase Inhibitors And Their Use For Treatment Of Cancer And Other Diseases Related To KinasesAug 15, 2019 · Application 16190669Pending
- Novel Compositions And Methods For Cancer TreatmentAug 13, 2019 · US 10,377,731Granted
- 3-(ARYL Or Heteroaryl) METHYLENEINDOLIN-2-ONE Derivatives As Inhibitors Of Cancer Stem Cell Pathway Kinases For The Treatment Of CancerAug 8, 2019 · Application 16206010Pending
- Heterocyclic SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DerivativeAug 8, 2019 · Application 16157370Pending
- Methods For Treating CancerAug 1, 2019 · Application 16363427Pending
- Methods For Treating CancerJul 25, 2019 · Application 16363626Pending
- Bacteria-Mediated Gene Modulation Via microRNA MachineryMar 21, 2019 · Application 16045128Pending
- Methods For Treating CancerMar 14, 2019 · Application 16070748Pending
- Method For Treating Cancer With A STAT3 Pathway Inhibitor And Kinase InhibitorSep 6, 2018 · Application 15569236Pending
- Methods For Treating CancerSep 6, 2018 · Application 15567061Pending
- Novel Compounds And Compositions For Targeting Cancer Stem CellsJul 12, 2018 · Application 15863132Pending
- Novel Methods For Treating CancerJul 12, 2018 · Application 15706240Pending
- 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE Derivative Or Pharmaceutically Acceptable Salt ThereofJul 10, 2018 · US 10,017,488Granted
- Compositions Comprising A Cancer Stemness Inhibitor And An Immunotherapeutic Agent For Use In Treating CancerMay 24, 2018 · Application 15579013Pending
- Methods For Treating CancerApr 12, 2018 · Application 15567070Pending
- Methods For Treating CancerMar 29, 2018 · Application 15566919Pending
- Novel Compositions And Methods For Cancer TreatmentFeb 1, 2018 · Application 15647054Pending
- Novel Group Of STAT3 Pathway Inhibitors And Cancer Stem Cell Pathway InhibitorsFeb 1, 2018 · Application 15655366Pending
- Compositions Of Kinase Inhibitors And Their Use For Treatment Of Cancer And Other Diseases Related To KinasesJan 25, 2018 · Application 15643608Pending
- Novel STAT3 Pathway Inhibitors And Cancer Stem Cell InhibitorsDec 5, 2017 · US 9,834,532Granted
- Novel Methods For Targeting Cancer Stem CellsNov 9, 2017 · Application 15642105Pending
- Novel Methods for Treating CancerOct 24, 2017 · US 9,795,595Granted
- Novel Methods For Targeting Cancer Stem CellsAug 15, 2017 · US 9,730,909Granted
- Compositions Of Kinase Inhibitors And Their Use For Treatment Of Cancer And Other Diseases Related To KinasesAug 8, 2017 · US 9,725,444Granted
- Novel STAT3 Pathway Inhibitors And Cancer Stem Cell InhibitorsJul 13, 2017 · Application 15429939Pending
- Asymmetric Interfering Rna Compositions That Silence K-ras And Methods Of Uses ThereofJan 19, 2017 · Application 15125655Pending
- New Tricyclic Quinone DerivativeJan 19, 2017 · Application 15300917Pending
- Novel Compounds And Compositions For Targeting Cancer Stem CellsSep 22, 2016 · Application 15169315Pending
- Novel Compounds And Compositions For Targeting Cancer Stem CellsJul 5, 2016 · US 9,381,184Granted
- Heterocyclic SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DerivativeMar 17, 2016 · Application 14950347Pending
- 2-ACETYLNAPHTHO[2,3-B]FURAN -4,9-DIONE For Use On Treating CancerFeb 4, 2016 · Application 14783184Pending
- 3-(ARYL Or Heteroaryl) METHYLENEINDOLIN-2-ONE Derivatives As Inhibitors Of Cancer Stem Cell Pathway Kinases For The Treatment Of CancerFeb 4, 2016 · Application 14774803Pending
- Inhibitors Of Kinases And Cancer Stem Cells, And Methods Of Preparation And Use ThereofNov 17, 2015 · US 9,187,454Granted
- Naphthofuran Derivatives, Preparation, And Methods Of Use ThereofApplication PCTUS2017063734Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .